EUVIMEDEUVIMED entdecken
Open Access

Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma

Bozhi Liu iD, Ant Murphy iD, Annaleigh Benton iD, Lauren Gartenhaus iD, William Budka, Juliana M Bronzini iD, Samuel Hartzler iD, Madison E Yates, Alejandra Romero Alzate iD, Nimod D Janson iD, Shyaman Jayasundara iD, Sagar Utturkar iD und 3 weitere

RNA · 2026

DOI: 10.1261/rna.080706.125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift RNA, 2026. Verfasst von Bozhi Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47906, USA. Hauptthemen laut MEDLINE: MicroRNAs, Hemangiosarcoma, Enoxacin. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiosarcoma (AS) is a rare and aggressive tumor arising within the endothelium, characterized by a high metastatic rate and poor prognosis. Our prior work established that endothelial loss of Dicer1, a key enzyme in microRNA (miRNA) processing, drives AS formation in mice, indicating a tumor suppressive role for miRNAs in tumorigenesis. Here, we corroborated this hypothesis by generating a novel conditional knockout model targeting Dgcr8, a core component of the microprocessor complex required for pri-miRNA processing. Conditional deletion of Dgcr8 phenocopies Dicer1 loss, resulting in spontaneous AS formation and global loss of mature miRNAs. We further demonstrate that treatment with enoxacin (ENX), a repurposed antibiotic known to enhance miRNA processing, reduces viability, migration, and clonogenicity of AS cells. ENX increases the abundance of tumor-suppressive miRNAs and downregulates oncogenic pathways, including pathways related to cell cycle progression, angiogenesis, and cell migration. These results establish the essential role of miRNA biogenesis in suppressing AS and reveal a pharmacologically targetable vulnerability via ENX-mediated enhancement of miRNA expression in tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsHemangiosarcomaEnoxacinAnimalsMiceHumansCell MovementRibonuclease IIIGene Expression Regulation, NeoplasticDEAD-box RNA HelicasesRNA-Binding ProteinsCell Line, TumorMice, Knockout

Stichwörter der Autor:innen

angiosarcomaenoxacinmiRNAsarcoma

Substanzen

MicroRNAsEnoxacinRibonuclease IIIDEAD-box RNA HelicasesRNA-Binding ProteinsDGCR8 protein, human

Autor:innen und Institutionen

  • Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47906, USA.
  • Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana 47906, USA.
  • Department of Biochemistry and Computer Science, Purdue University, West Lafayette, Indiana 47906, USA.
  • Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana 47906, USA.
  • Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47906, USA hannaja@purdue.edu.

ORCID-Profile: Bozhi Liu, Ant Murphy, Annaleigh Benton, Lauren Gartenhaus, Juliana M Bronzini, Samuel Hartzler, Alejandra Romero Alzate, Nimod D Janson, Shyaman Jayasundara, Sagar Utturkar, Nadia A Lanman, Majid Kazemian, Jason A Hanna

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Liu, B., Murphy, A., Benton, A., Gartenhaus, L., Budka, W., Bronzini, J. M., Hartzler, S., Yates, M. E., Alzate, A. R., Janson, N. D., Jayasundara, S., Utturkar, S., Lanman, N. A., Kazemian, M., & Hanna, J. A. (2026). Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma. RNA. https://doi.org/10.1261/rna.080706.125

Vancouver

Liu B, Murphy A, Benton A, Gartenhaus L, Budka W, Bronzini JM, et al. Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma. RNA. 2026. doi:10.1261/rna.080706.125

BibTeX
@article{Liu2026,
  author = {Liu, Bozhi and Murphy, Ant and Benton, Annaleigh and Gartenhaus, Lauren and Budka, William and Bronzini, Juliana M and Hartzler, Samuel and Yates, Madison E and Alzate, Alejandra Romero and Janson, Nimod D and Jayasundara, Shyaman and Utturkar, Sagar and Lanman, Nadia A and Kazemian, Majid and Hanna, Jason A},
  title = {Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma},
  journal = {RNA},
  year = {2026},
  doi = {10.1261/rna.080706.125}
}
Kostenlos starten →